Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy
Annals of Hematology · 2024-03 · 103 (3) · 969-980
DOI: 10.1007/s00277-024-05617-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 12.01.2024. Verfasst von Yifan Zhao und 13 weiteren Autor:innen. Beteiligte Einrichtung: The First Central Clinical College of Tianjin Medical University, Tianjin, 300380, China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Leukemia, Myeloid, Acute, Neurotoxicity Syndromes. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Chimeric antigen receptor T (CAR-T) cell therapy targeting CLL1 has been considered a potent weapon for patients with acute myeloid leukemia (AML). This study aims to evaluate the efficacy and toxicity of CLL1 CAR-T cell therapy in a larger cohort, with particular attention to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Among the 32 patients assessed for efficacy, complete remission occurred in 71.88% (23/32) of cases and undetectable minimal residual disease in 14 patients. The CRS developed in all patients, with 8 individuals experiencing ICANS. Severe CRS and ICANS were observed in 11 and 2 patients, respectively. Furthermore, the Endothelial Activation and Stress Index (EASIX) and its derivatives measured before and after CLL1 CAR-T cell infusion were employed for predicting the severe complications. Significant differences were observed in EASIX scores on the day before lymphodepletion (Day BL, P = 0.023), -1 (P < 0.001), +1 (P < 0.001), and +3(P = 0.014); sEASIX scores on Day BL (P = 0.007), -1 (P < 0.001), +1 (P < 0.001), and +3 (P < 0.001); and mEASIX score on Day -1 (P = 0.004) between patients with mild and severe CRS/ICANS. Additionally, there was a significant difference in mEASIX scores between responders and non-responders on Day BL (P = 0.004) and Day -1 (P = 0.044). Our findings indicate that pre- and post-infusion assessments of EASIX/mEASIX/sEASIX scores serve as reliable prognostic indicators for severe CRS/ICANS and treatment response following CLL1 CAR-T cell therapy, which can assist physicians in implementing preemptive treatment strategies for potential severe complications and screening patients who are suitable candidates for CLL1 CAR-T cell therapy. EASIX/mEASIX/sEASIX scores serve as reliable prognostic indicators for severe CRS/ICANS following CLL1 CAR-T cell therapy. The preinfusion mEASIX scores of CLL1 CAR-T cells can effectively predict treatment response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Central Clinical College of Tianjin Medical University, Tianjin, 300380, China.
- Nankai University School of Medicine, Tianjin, 300380, China.
- Department of Hematology, Tianjin First Central Hospital, Tianjin, 300380, China.
- Department of Hematology, Tianjin First Central Hospital, Tianjin, 300380, China. xxiiaao@126.com.
- Department of Hematology, Tianjin First Central Hospital, Tianjin, 300380, China. mingfengzhao@sina.com.
Zitieren
APA
Zhao, Y., Zhang, X., Zhang, M., Guo, R., Zhang, Y., Pu, Y., Zhu, H., Liu, P., Zhang, Y., He, X., Lyu, C., Lyu, H., Xiao, X., & Zhao, M. (2024). Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy. Annals of Hematology, 103(3), 969-980. https://doi.org/10.1007/s00277-024-05617-y
Vancouver
Zhao Y, Zhang X, Zhang M, Guo R, Zhang Y, Pu Y, et al. Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy. Annals of Hematology. 2024;103(3):969-980. doi:10.1007/s00277-024-05617-y
BibTeX
@article{Zhao2024,
author = {Zhao, Yifan and Zhang, Xiaomei and Zhang, Meng and Guo, Ruiting and Zhang, Yi and Pu, Yedi and Zhu, Haibo and Liu, Pengjiang and Zhang, Yu and He, Xiaoyuan and Lyu, Cuicui and Lyu, Hairong and Xiao, Xia and Zhao, Mingfeng},
title = {Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy},
journal = {Annals of Hematology},
year = {2024},
volume = {103},
number = {3},
pages = {969--980},
doi = {10.1007/s00277-024-05617-y}
}
EUVIMED